Literature DB >> 23323725

Selected protein monitoring in histological sections by targeted MALDI-FTICR in-source decay imaging.

David Calligaris1, Rémi Longuespée, Delphine Debois, Daiki Asakawa, Andrei Turtoi, Vincent Castronovo, Agnès Noël, Virginie Bertrand, Marie-Claire De Pauw-Gillet, Edwin De Pauw.   

Abstract

Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) is a rapidly growing method in biomedical research allowing molecular mapping of proteins on histological sections. The images can be analyzed in terms of spectral pattern to define regions of interest. However, the identification and the differential quantitative analysis of proteins require off line or in situ proteomic methods using enzymatic digestion. The rapid identification of biomarkers holds great promise for diagnostic research, but the major obstacle is the absence of a rapid and direct method to detect and identify with a sufficient dynamic range a set of specific biomarkers. In the current work, we present a proof of concept for a method allowing one to identify simultaneously a set of selected biomarkers on histological slices with minimal sample treatment using in-source decay (ISD) MSI and MALDI-Fourier transform ion cyclotron resonance (FTICR). In the proposed method, known biomarkers are spotted next to the tissue of interest, the whole MALDI plate being coated with 1,5-diaminonaphthalene (1,5-DAN) matrix. The latter enhances MALDI radical-induced ISD, providing large tags of the amino acid sequences. Comparative analysis of ISD fragments between the reference spots and the specimen in imaging mode allows for unambiguous identification of the selected biomarker while preserving full spatial resolution. Moreover, the high resolution/high mass accuracy provided by FTICR mass spectrometry allows the identification of proteins. Well-resolved peaks and precise measurements of masses and mass differences allow the construction of reliable sequence tags for protein identification. The method will allow the use of MALDI-FTICR MSI as a method for rapid targeted biomarker detection in complement to classical histology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23323725     DOI: 10.1021/ac302746t

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  13 in total

Review 1.  Mass spectrometry imaging, an emerging technology in neuropsychopharmacology.

Authors:  Mohammadreza Shariatgorji; Per Svenningsson; Per E Andrén
Journal:  Neuropsychopharmacology       Date:  2013-08-21       Impact factor: 7.853

2.  Organic washes of tissue sections for comprehensive analysis of small molecule metabolites by MALDI MS imaging of rat brain following status epilepticus.

Authors:  Hui Yang; Wenliang Ji; Ming Guan; Shilei Li; Yangyang Zhang; Zhenwen Zhao; Lanqun Mao
Journal:  Metabolomics       Date:  2018-03-14       Impact factor: 4.290

3.  HFIP extraction followed by 2D CTAB/SDS-PAGE separation: a new methodology for protein identification from tissue sections after MALDI mass spectrometry profiling for personalized medicine research.

Authors:  Rémi Longuespée; Christophe Tastet; Annie Desmons; Olivier Kerdraon; Robert Day; Isabelle Fournier; Michel Salzet
Journal:  OMICS       Date:  2014-05-19

4.  3-Hydroxy-2-Nitrobenzoic Acid as a MALDI Matrix for In-Source Decay and Evaluation of the Isomers.

Authors:  Yuko Fukuyama; Shunsuke Izumi; Koichi Tanaka
Journal:  J Am Soc Mass Spectrom       Date:  2018-07-30       Impact factor: 3.109

5.  5-nitrosalicylic Acid as a novel matrix for in-source decay in matrix-assisted laser desorption/ionization mass spectrometry.

Authors:  Daiki Asakawa
Journal:  Mass Spectrom (Tokyo)       Date:  2013-05-15

6.  The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.

Authors:  Jenny L Pokorny; David Calligaris; Shiv K Gupta; Dennis O Iyekegbe; Dustin Mueller; Katrina K Bakken; Brett L Carlson; Mark A Schroeder; Debra L Evans; Zhenkun Lou; Paul A Decker; Jeanette E Eckel-Passow; Vincenzo Pucci; Bennett Ma; Stuart D Shumway; William F Elmquist; Nathalie Y R Agar; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

7.  Monitoring therapeutic monoclonal antibodies in brain tumor.

Authors:  Rima Ait-Belkacem; Caroline Berenguer; Claude Villard; L'Houcine Ouafik; Dominique Figarella-Branger; Alain Beck; Olivier Chinot; Daniel Lafitte
Journal:  MAbs       Date:  2014       Impact factor: 5.857

8.  MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation.

Authors:  David Calligaris; Daniel R Feldman; Isaiah Norton; Olutayo Olubiyi; Armen N Changelian; Revaz Machaidze; Matthew L Vestal; Edward R Laws; Ian F Dunn; Sandro Santagata; Nathalie Y R Agar
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

Review 9.  Current status and future perspectives of mass spectrometry imaging.

Authors:  Surendra Nimesh; Susantha Mohottalage; Renaud Vincent; Prem Kumarathasan
Journal:  Int J Mol Sci       Date:  2013-05-28       Impact factor: 5.923

10.  Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Authors:  Rémi Longuespée; Frédéric Couture; Christine Levesque; Anna Kwiatkowska; Roxane Desjardins; Sandra Gagnon; Daniele Vergara; Michelle Maffia; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2014-05-09       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.